NuCana plc has initiated an expansion study of its anti-cancer drug NUC-7738 combined with pembrolizumab for patients with melanoma resistant to PD-1 inhibitors, with initial data expected in Q4 2025 ...
The KEYTRUDA regimen is the first and only PD-1 inhibitor-based treatment approved in the European Union for these patients Approval supported by data from the Phase 3 KEYNOTE-B96 trial in which the ...
With Bristol Myers Squibb (BMS) now rolling out the SC version of rival nivolumab (Opdivo Qvantig), the shift from 30-minute intravenous (IV) infusion to 5-minute SC injection could be one of the most ...
Pembrolizumab, an immune checkpoint inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with resectable locally advanced head and neck squamous ...
Pembrolizumab (Keytruda, Merck Sharp & Dohme) is a humanised monoclonal antibody that acts on the 'programmed death 1' protein (PD‑1). The PD‑1 protein is part of the immune checkpoint pathway, and ...
Triple-negative breast cancer is an aggressive breast cancer subtype, and there remains an unmet need to improve outcomes in patients with previously untreated, programmed death ligand 1 ...
Synthekine Announces Clinical Trial Collaboration with Merck to Evaluate STK-012 In Combination with Keytruda® (Pembrolizumab) and Chemotherapy in Ongoing Randomized Phase 2 Trial in First-Line, PD-L1 ...
Please provide your email address to receive an email when new articles are posted on . The FDA approved pembrolizumab regimens for patients with PD-L1 positive, platinum-resistant ovarian cancers. A ...
The benefit of the addition of perioperative pembrolizumab to standard care with surgery and adjuvant therapy for patients with locally advanced head and neck squamous-cell carcinoma (HNSCC) is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results